Marshall Wace’s CTI BioPharma CTIC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-5,960,103
Closed -$25M – 3227
2023
Q1
$25M Buy
+5,960,103
New +$30.9M 0.05% 386
2022
Q2
– Sell
-862,383
Closed -$4.03M – 4096
2022
Q1
$4.03M Buy
862,383
+773,293
+868% +$2.31M 0.01% 1538
2021
Q4
$221K Hold
89,090
– – ﹤0.01% 3127
2016
Q4
$60K Buy
+15,000
New +$62.2K ﹤0.01% 946

Other funds holding CTIC

Marshall Wace's CTIC Position: Q2 2023 in Review

Marshall Wace sold out of CTI BioPharma (CTIC) in Q2 2023, closing a stake of 5,960,103 shares — an estimated $25M sold.

Marshall Wace first reported a position in CTIC in Q4 2016 and held it in 4 quarters. The position peaked at $25M in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

  • Marshall Wace reported no remaining CTI BioPharma position as of Q2 2023 after selling out during the quarter.
  • Marshall Wace sold 5,960,103 CTI BioPharma shares in Q2 2023, an estimated $25M.
  • Marshall Wace first reported a position in CTI BioPharma in Q4 2016 and held it in 4 quarters.
  • Marshall Wace's CTI BioPharma position peaked at $25M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held CTI BioPharma as of Q2 2023.

Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.